Plasma Melatonin AND Mortality After Acute Myocardial Infarction

Completed

• Conditions: Melatonin; Myocardial Infarction

• Registration Number: NCT03230630
• Lead Sponsor: Chinese PLA General Hospital

Brief Summary

Pre-clinical and clinical studies have demonstrated that melatonin has cardio-protection effects. Melatonin has anti-inflammatory, antioxidant, antihypertensive, antithrombotic and antilipaemic properties, which plays important roles in a variety of cardiovascular pathophysiologic processes. Nocturnal melatonin levels decreased after AMI, and lower serum melatonin concentrations after AMI are associated with more heart failure and cardiac death and left ventricular remodeling. Moreover in women with increased BMI, lower melatonin secretion is associated with higher risks of MI. Early-morning blood collection is easier in clinical practice. Therefore, the investigators carried out a cohort study to evaluate the prognostic value of plasma soluble melatonin in hospitalized patients with acute myocardial infarction (AMI).

Detailed Description

Not available

Study Timeline

• Study Start: 2013-01-01
• Primary Completion: 2015-01-01
• Study Completion: 2017-01-01
• Status Verified: 2017-07
• Study First Submitted: 2017-07-24
• Study First Submitted QC: 2017-07-24
• Last Update Submitted: 2017-07-25
• Study First Posted: 2017-07-26
• Last Update Posted: 2017-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 732

Inclusion Criteria

• consecutive patients of acute AMI come to department of cardiology, 301 hospital (Beijing, China),absent of cardiogenic shock, and survival for at least 24 h after percutaneous coronary intervention treatment.

Exclusion Criteria

• patients with autoimmune diseases, collagen tissue diseases, drug addiction, radiotherapy, patients receiving immunosuppressive treatment, taking sedatives, antiepileptic drugs, tricyclic antidepressants or any medication known to influence melatonin metabolism, psychiatric sleeping disorders, shift workers, and subjects with jet-lag syndrome

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
cardiovascular mortality	The median follow-up was 31.6 months

Secondary Outcome Measures

Name	Time	Method
heart failure readmission	The median follow-up was 31.6 months	readmission to any hospital due to diagnosed heart failure
Stroke	The median follow-up was 31.6 months	defined using the World Health Organization criteria
non-cardiovascular mortality	The median follow-up was 31.6 months
Myocardial infarction	The median follow-up was 31.6 months